News | Women's Health | October 01, 2019

Volpara's volumetric breast imaging tools help maintain accuracy and consistency in screening

Volpara's breast density scale

Levels of breast density.


Celebrating its 10th Anniversary in 2019, Volpara Solutions remains committed to helping breast imaging centers achieve improved mammographic sensitivity and detect breast cancers earlier. Since launching Volpara Density  software in 2010, the company has pioneered a robust suite of quantitative breast imaging tools that enable personalized measurements of volumetric density, breast compression, and breast positioning on every mammogram—factors designed to maintain image quality and provide critical insight for breast imaging workflow.

Volpara boasts many accomplishments in its 10-year history. Some of the most notable include the following:

  • Over 100 peer-reviewed papers, making VolparaDensity the most clinically validated automatic, volumetric breast density assessment software in the world

  • Density assessments for more than 20 million women across 37 countries

  • Software installed in more than 300 leading facilities worldwide, including the top two cancer centers in the United States, according to the latest hospital rankings from US News & World Report

  • More than 1 million mammographic and tomosynthesis studies evaluated for positioning and compression stored in the Volpara Enterprise cloud

  • Recurring revenue growth of over 3,000% since listing on the ASX in 2016

"Volpara was founded for very personal reasons, as we each had friends and family members die of breast cancer. However, with more than 500,000 breast cancers deaths worldwide each year, our vision quickly expanded to a focus on helping save all families from breast cancer," said Ralph Highnam, PhD, founder and CEO, Volpara Solutions. "Building on the hugely successful adoption of VolparaDensity over the past 10 years, we have been able to make women and physicians understand the importance of breast density and help shift the conversation to risk and personalized medicine. We are extremely proud of the progress we've made and thank all of our employees, industry partners, researchers, and customers as we look forward to the next 10 years of progress."

According to Highnam, the achievements of the first 10 years may best be summarized by a recent customer comment: "with Volpara, we are making screening more accurate, more comfortable, safer, more cost-effective and making a difference daily."

For more information: www.volpara.com 


Related Content

News | Radiology Business

April 23, 2024 — A diverse writing group—lead by authors at the University of Toronto—have developed an approach for ...

Time April 23, 2024
arrow
News | Artificial Intelligence

April 19, 2024 — Large language model GPT-4 matched the performance of radiologists in detecting errors in radiology ...

Time April 22, 2024
arrow
News | Computed Tomography (CT)

April 22, 2024 — A new study showed that a non-invasive imaging test can help identify patients with coronary artery ...

Time April 22, 2024
arrow
News | FDA

April 18, 2024 — Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging ...

Time April 18, 2024
arrow
News | Mammography

April 16, 2024 — The Radiological Society of North America (RSNA) and GE HealthCare announced their collaboration to ...

Time April 16, 2024
arrow
News | Clinical Trials

April 16, 2024 — QT Imaging Holdings, Inc., a medical device company engaged in research, development, and ...

Time April 16, 2024
arrow
Videos | Breast Imaging

Don't miss ITN's latest "One on One" video interview with AAWR Past President and American College of Radiology (ACR) ...

Time April 15, 2024
arrow
News | Mammography

April 12, 2024 — Bayer and Hologic, Inc. announced a first-of-its-kind collaboration to deliver a coordinated solution ...

Time April 12, 2024
arrow
News | Mammography

April 12, 2024 — GE HealthCare, a leader in breast health technology and diagnostics, will feature its latest breast ...

Time April 12, 2024
arrow
News | Radiation Dose Management

April 11, 2024 — Prelude Corporation (PreludeDx), a leader in precision diagnostics for early-stage breast cancer ...

Time April 11, 2024
arrow
Subscribe Now